Archives: Agenda

AI is powerful, but the drug and the patient come first. This boardroom explores how teams can leverage AI safely, integrate it into workflows, and maintain human control with strong processes.

Outcome: Each table will collaborate to create practical strategies, and governance approaches that balance AI capabilities with human oversight, ensuring AI enhances decisions rather than replacing critical thinking.

A variety of alcoholic and soft drinks will be served

AI is powerful, but the drug and the patient come first. This boardroom explores how teams can leverage AI safely, integrate it into workflows, and maintain human control with strong processes.

Outcome: Each table will collaborate to create practical strategies, and governance approaches that balance AI capabilities with human oversight, ensuring AI enhances decisions rather than replacing critical thinking.

A variety of alcoholic and soft drinks will be served

• How to reposition CTS from a pure logistics function to a strategic partner and enable teams to advocate their value internally to improve ClinOps outcomes
• Protocol vs. Reality: How to close the gap between protocol design and operational reality through early collaboration to ensure the supply chain matches the realities of patient care
• How to establish shared goals, KPIs, and communication frameworks between CTS and ClinOps to sustain alignment and ongoing collaboration throughout the study

• How to safeguard temperature-sensitive biologics and advanced therapies during shipping delays
• How to stay compliant with local and global regulations while maintaining chain-custody
• How to select validated storage facilities for all temperature ranges while keeping inventory visible and minimizing loss

• How to align CDMO partnerships with phase-specific needs while staying agile
• How to collaborate across CDMOs and ensure smooth tech transitions, especially for biologics therapies
• How to build transparent CDMO partnerships from Day 1 to overcome challenges and save costs

• Aligning Manufacturing, Regulatory, and Clinical Operations to eliminate silos and enable integrated, compliant decision-making
• Establishing governance and ownership frameworks linking supply execution with financial planning to drive transparency, accountability, and aligned decisions
• Identifying and resolving end-to-end process bottlenecks to improve agility, reduce risk, and ensure supply continuity across clinical and commercial programs